These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

630 related items for PubMed ID: 10070965

  • 1. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors.
    Marzo AL, Lake RA, Robinson BW, Scott B.
    Cancer Res; 1999 Mar 01; 59(5):1071-9. PubMed ID: 10070965
    [Abstract] [Full Text] [Related]

  • 2. Cellular mechanisms involved in protection against influenza virus infection in transgenic mice expressing a TCR receptor specific for class II hemagglutinin peptide in CD4+ and CD8+ T cells.
    Bot A, Casares S, Bot S, von Boehmer H, Bona C.
    J Immunol; 1998 May 01; 160(9):4500-7. PubMed ID: 9574556
    [Abstract] [Full Text] [Related]

  • 3. Induction and maintenance of T-cell response to a nonimmunogenic murine mesothelioma cell line requires expression of B7-1 and the capacity to upregulate class II major histocompatibility complex expression.
    Leong C, Marley J, Loh S, Robinson B, Garlepp M.
    Cancer Gene Ther; 1996 May 01; 3(5):321-30. PubMed ID: 8894251
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Class I- and class II-reactive TCRs coexpressed on CD4+ T cells both trigger CD4/CD8-shared and CD4-unique functions.
    Asnagli H, Schmitt-Verhulst AM, Guimezanes A.
    J Immunol; 1997 May 15; 158(10):4533-42. PubMed ID: 9144464
    [Abstract] [Full Text] [Related]

  • 9. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
    Huang H, Li F, Gordon JR, Xiang J.
    Cancer Res; 2002 Apr 01; 62(7):2043-51. PubMed ID: 11929823
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Antigen recognition and allogeneic tumor rejection in CD8+ TCR transgenic/RAG(-/-) mice.
    Manning TC, Rund LA, Gruber MM, Fallarino F, Gajewski TF, Kranz DM.
    J Immunol; 1997 Nov 15; 159(10):4665-75. PubMed ID: 9366389
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
    May RJ, Dao T, Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, Zhang RH, Maslak P, Scheinberg DA.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4547-55. PubMed ID: 17671141
    [Abstract] [Full Text] [Related]

  • 15. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
    Teramoto K, Kontani K, Ozaki Y, Sawai S, Tezuka N, Nagata T, Fujino S, Itoh Y, Taguchi O, Koide Y, Asai T, Ohkubo I, Ogasawara K.
    Cancer Res; 2003 Nov 15; 63(22):7920-5. PubMed ID: 14633722
    [Abstract] [Full Text] [Related]

  • 16. Anti-class II antibodies, but not cytotoxic T-lymphocyte antigen 4-immunoglobulin hybrid molecules, prevent rejection of major histocompatibility complex class II-negative myeloma in T-cell receptor-transgenic mice.
    Dembic Z, Hofgaard PO, Omholt H, Bogen B.
    Scand J Immunol; 2004 Nov 15; 60(1-2):143-52. PubMed ID: 15238083
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The immunologic function of 1B2+ double negative (CD4-CD8-) T cells in the 2C transgenic mouse.
    Margenthaler JA, Flye MW.
    J Surg Res; 2005 Jun 15; 126(2):160-6. PubMed ID: 15919414
    [Abstract] [Full Text] [Related]

  • 20. Naive CD4+ T cells confer idiotype-specific tumor resistance in the absence of antibodies.
    Bogen B, Munthe L, Sollien A, Hofgaard P, Omholt H, Dagnaes F, Dembic Z, Lauritzsen GF.
    Eur J Immunol; 1995 Nov 15; 25(11):3079-86. PubMed ID: 7489746
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.